Postdoctoral Research Associate
Washington University, School of Medicine in St. Louis
Dr. Sankar has been a Postdoctoral Research Associate at Washington University, School of Medicine in St. Louis. Her post-doctoral research focused on understanding mechanisms of transcriptional and epigenetic regulations that drive normal development using stem cells as a model and that drive oncogenesis in pediatric high-grade gliomas and in medullobastoma brain tumors. Her PhD thesis research was focused on elucidating mechanisms of transcriptional and epigenetic control by a chromosomal translocation-derived fusion oncoprotein, EWS/FLI, in a pediatric malignancy called Ewing sarcoma utilizing state-of-the art molecular biology techniques like RNA-seq and ChIP-seq. Dr. Sankar characterized the mechanistic role of an epigenetic protein LSD1 in EWS/FLI-mediated gene activation and gene repression and developed a novel reversible LSD1 inhibitor in collaboration with the Center for Investigational Therapeutics at the Huntsman Cancer Institute as a targeted therapeutic agent for Ewing sarcoma patients. Dr. Sankar has authored several first author and co-author publications and has extensive experience in reviewing research articles. She has over ten years of continuous work experience in the field on molecular & cellular biology and oncology. Dr. Sankar is the editorial board member for International Journal of Oncotherapy and is a reviewer for several journals including, MJD, MBOC, MIB, BMC-Biology, Development, Stem cells, BBMG, IAM, IMED, JCT, MCBI and OMICS Cancer Group. Dr. Sankar is a member of the American Association of Cancer Research (AACR). Dr. Sankar has received clinical and translational research training from the prestigious HHMI-Med to Grad program at the University of Utah, Salt Lake City.